University Research Lecturer
José Leal joined the Health Economics Research Centre in January 2004, having completed his MSc in Health Economics at the University of York in 2003. Since joining HERC, José has worked on several projects, including an economic evaluation of genetic testing for sudden cardiac death, an economic evaluation of MS/MS screening for Medium Chain Acyl-CoenzymeA Dehydrogenase Deficiency, elicitation of expert opinion and several cost-of-illness studies.
José has recently completed a doctoral thesis at the University of Oxford on the use of multi-parameter evidence synthesis to inform economic evaluations. His current research interests include the use of expert opinion to inform decision models, evidence synthesis frameworks in economic evaluation and individual patient level modelling.
Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
Becker F. et al, (2018), Diabetologia, 61, S366 - S366
Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
Reed SD. et al, (2018), Diabetologia, 61, S426 - S426
Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
Mc Morrow L. et al, (2018), Diabetologia, 61, S344 - S344
Risk attitudes of people with 'manageable' chronic disease: An analysis under prospect theory.
Rouyard T. et al, (2018), Soc sci med, 214, 144 - 153
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD. et al, (2018), Diabetes obes metab, 20, 1732 - 1739